Monomethyl triazeno imidazole carboxamide

CAS : 3413-72-7

Ref. 3D-FM26098

Informations sur le produit

• Nom: Monomethyl triazeno imidazole carboxamide
• Synonymes: MTIC3-methyl(triazenyl)imidazole-4-carboxamide5-(3-methyltriazen-1-yl)imidazole-4-carboxamide, NSC 407347

Description

Monomethyl triazeno imidazole carboxamide (MTIC) is a drug that is used to treat cancer. It has been shown to inhibit the proliferation of tumor cells and induce apoptosis by inhibiting the expression of proteins, such as Bcl-2, which are involved in regulating mitochondrial membrane potential. MTIC has also been shown to inhibit protein synthesis and cell signaling pathways, such as the PI3K/Akt pathway. The use of MTIC for diagnosis purposes can be achieved using electrochemical impedance spectroscopy. A concentration-time curve can be obtained by incubating a biological sample with MTIC and measuring cell response using an impedance spectrophotometer. The clinical properties of MTIC include its ability to be administered orally or intravenously, have low toxicity, and inhibit the growth of tumor cells in vivo and in vitro.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 168.16 g/mol
• Formule: C₅H₈N₆O
• Degré de pureté: (¹H-Nmr) Min. 95 Area-%
• Couleur/Forme: White Powder
• InChI: InChI=1S/C5H8N6O/c1-7-11-10-5-3(4(6)12)8-2-9-5/h2H,1H3,(H2,6,12)(H,7,10)(H,8,9)
• Code InChI: InChIKey=MVBPAIHFZZKRGD-UHFFFAOYSA-N
• SMILES: C/N=N/Nc1nc[nH]c1C(N)=O